INBX
Inhibrx Inc
Price:  
11.26 
USD
Volume:  
108,318.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

INBX WACC - Weighted Average Cost of Capital

The WACC of Inhibrx Inc (INBX) is 8.9%.

The Cost of Equity of Inhibrx Inc (INBX) is 10.55%.
The Cost of Debt of Inhibrx Inc (INBX) is 9.85%.

Range Selected
Cost of equity 9.20% - 11.90% 10.55%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 7.00% - 12.70% 9.85%
WACC 7.2% - 10.6% 8.9%
WACC

INBX WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 1.16 1.26
Additional risk adjustments 0.0% 0.5%
Cost of equity 9.20% 11.90%
Tax rate 26.20% 27.00%
Debt/Equity ratio 1 1
Cost of debt 7.00% 12.70%
After-tax WACC 7.2% 10.6%
Selected WACC 8.9%

INBX's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for INBX:

cost_of_equity (10.55%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (1.16) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.